New study links GLP-1 treatments to reduced cancer risk

Researchers examined the medical records of 1.6 million diabetes patients and found a ”significant risk reduction” for 10 obesity-related cancers. 
Novo Nordisk's product Ozempic was approved in 2017. | Photo: Lee Smith/Reuters/Ritzau Scanpix
Novo Nordisk's product Ozempic was approved in 2017. | Photo: Lee Smith/Reuters/Ritzau Scanpix

Type 2 diabetes patients using GLP-1 therapies, including Novo Nordisk’s Ozempic, rather than insulin and other diabetes medications have a lower risk of developing a number of obesity-related cancers, according to a new study published Friday in the medical journal Jama Network Open.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Foto: Mike Blake/Reuters/Ritzau Scanpix

    Gilead Sciences CMO to leave early 2025

    For subscribers

    Further reading